[1]	Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. the galantamine USA-10 study group[J]. Neurology, 2000, 54(12): 2269-2276. Cited in this article [2]

[2]	Rockwood K, Fay S, Song X, et al. Attainment of treatment goals by people with Alzheimer’s disease receiving galantamine: a randomized controlled trial[J]. CMAJ, 2006, 174(8): 1099-1105. Cited in this article [1]

[3]	Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group[J]. Arch Intern Med, 1998, 158(9): 1021-1031. Cited in this article [1]

[4]	Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. the galantamine USA-1 study group[J]. Neurology, 2000, 54(12): 2261-2268. Cited in this article [2]

[5]	Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with alzheimer's disease: results of a us multicentre, randomized, double-blind, placebo-controlled trial. the donepezil study group[J]. Dement, 1996, 7(6):293-303. Cited in this article [1]

[6]	Molinuevo JL, Berthier ML, Rami L, et al. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment[J]. Arch Gerontol Geriatr, 2011, 52(1): 18-22. Cited in this article [1]

[7]	Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial[J]. BMJ, 1999, 318(7184): 633-638. Cited in this article [1]

[8]	Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial[J]. Lancet, 2004, 363(9427): 2105-2115. Cited in this article [1]

[9]	Pirttilä T, Wilcock G, Truyen L, et al. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial[J]. Eur J Neurol, 2004, 11(11): 734-741. Cited in this article [1]

[10]	Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis[J]. CMAJ, 2003, 169(6):557-564. Cited in this article [1]

[11]	Jia J, Wei C, Jia L, et al. Efficacy and safety of donepezil in chinese patients with severe Alzheimer’s disease: a randomized controlled trial[J]. J Alzheimers Dis, 2017, 56(4):1495-1504. Cited in this article [1]

[12]	Trinh NH, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis[J]. JAMA, 2003, 289(2):210-216. Cited in this article [1]

[13]	Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease[J]. Neurology, 2001, 57(4):613-620. Cited in this article [1]

[14]	Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial[J]. Arch Neurol, 2004, 61(12): 1852-1856. Cited in this article [1]

[15]	Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period[J]. Curr Med Res Opin, 2005, 21(8): 1317-1327. Cited in this article [1]

[16]	Wilkinson DG, Passmore AP, Bullock R, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease[J]. Int J Clin Pract, 2002, 56(6): 441-446. Cited in this article [1]

[17]	Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the american college of physicians and the american academy of family physicians[J]. Ann Intern Med, 2008, 148(5):370-378. Cited in this article [1]

[18]	Sheikh M, Ammar M. Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis[J]. Front Neurosci, 2024,18:1398952. Cited in this article [1]

[19]	Farlow MR, Salloway S, Tariot PN, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study[J]. Clin Ther, 2010, 32(7): 1234-1251. Cited in this article [1]

[20]	Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease--rivastigmine patch versus capsule[J]. Int J Geriatr Psychiatry, 2007, 22(5): 456-467. Cited in this article [1]

[21]	Blesa R, Ballard C, Orgogozo JM, et al. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease[J]. Neurology, 2007, 69(4): S23-28. Cited in this article [1]

[22]	Yang G, Wang Y, Tian J, et al. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials[J]. PLoS One, 2013, 8(9): e74916. Cited in this article [1]

[23]	Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial[J]. JAMA, 2004, 291(3): 317-324. Cited in this article [1]

[24]	Yang Z, Zhou X, Zhang Q, et al. Effectiveness and safety of memantine treatment for Alzheimer's disease[J]. J Alzheimers Dis, 2013, 36(3): 445-458. Cited in this article [1]

[25]	Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease[J]. Dement Geriatr Cogn Disord, 2007, 24(2): 138-145. Cited in this article [1]

[26]	Wilkinson D, Wirth Y, Goebel C, et al. Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response[J]. Dement Geriatr Cogn Disord, 2014, 37(1-2): 71-85. Cited in this article [1]

[27]	Gauthier S, Loft H, Cummings J, et al. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis[J]. Int J Geriatr Psychiatry, 2008, 23(5):537-545. Cited in this article [1]

[28]

Martinez C, Jones RW, Rietbrock S, et al. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study[J]. BMJ Open, 2013, 3(1):e002080. Cited in this article [1]

[29]	Matsunaga S, Kishi T, Iwata N, et al. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis[J]. PLoS One, 2015, 10(4):e0123289. Cited in this article [1]

[30]	Winblad B, Gauthier S, Aström D, et al. Memantine benefits functional abilities in moderate to severe Alzheimer's disease[J]. J Nutr Health Aging, 2010, 14(9): 770-774. Cited in this article [1]

[31]	Farlow MR, Graham SM, Alva G, et al. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials[J]. Drug Saf, 2008, 31(7): 577-585. Cited in this article [1]

[32]

Dantoine T, Auriacombe S, Sarazin M, et al. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment[J]. Int J Clin Pract, 2006, 60(1):110-118. Cited in this article [1]

[33]	中华医学会精神医学分会老年精神医学组. 神经认知障碍精神行为症状群临床诊疗专家共识[J]. 中华精神科杂志, 2017, 50(5):335-339,. Cited in this article [2]

[34]	中华医学会精神病学分会. 中国老年期痴呆防治指南[J]. 人民卫生出版社, 2021. Cited in this article [2]

[35]	Yunusa I, Alsumali A, Garba AE, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis[J]. JAMA Netw Open, 2019, 2(3): e190828. Cited in this article [2]

[36]	Huang YY, Teng T, Shen XN, et al. Pharmacological treatments for psychotic symptoms in dementia: a systematic review with pairwise and network meta-analysis[J]. Ageing Res Rev, 2022,75:101568. Cited in this article [1]

[37]	Sano M. Agitation in cognitive disorders: use of the national alzheimer's coordinating center uniform data set (NACC-UDS) to evaluate international psychogeriatric association definition[J]. Am J Geriatr Psychiatry, 2022, 30(11):1198-1208. Cited in this article [1]

[38]	Ballard C. Brexpiprazole for the treatment of agitation and aggression in Alzheimer disease[J]. JAMA Neurol, 2023, 80(12):1272-1273. Cited in this article [1]

[39]	Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial[J]. JAMA Neurol, 2023, 80(12):1307-1316. Cited in this article [1]

[40]	Grossberg GT, Kohegyi E, Mergel V, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials[J]. Am J Geriatr Psychiatry, 2020, 28(4): 383-400. Cited in this article [1]

[41]	Menegaz de Almeida A, Viana P, Marinheiro G, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials[J]. Neurol Sci, 2024, 45(10): 4679-4686. Cited in this article [1]

[42]	Tucker S, Möller C, Tegerstedt K, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice[J]. J Alzheimers Dis, 2015, 43(2):575-588. Cited in this article [2]

[43]	O' Nuallain B, Freir DB, Nicoll AJ, et al. Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils[J]. J Neurosci, 2010, 30(43):14411-14419. Cited in this article [1]

[44]	Nilsberth C, Danielsson WA, Eckman CB, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation[J]. Nat Neurosci, 2001, 4(9):887-893. Cited in this article [1]

[45]	Lord A, Gumucio A, Englund H, et al. An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease[J]. Neurobiol Dis, 2009, 36(3): 425-434. Cited in this article [1]

[46]	Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401 - a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody[J]. Alz Res Therapy, 2016, 8(1):14. Cited in this article [1]

[47]	Satlin A, Wang J, Logovinsky V, et al. Design of a bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease[J]. Alzheimers Dement(N Y), 2016, 2(1): 1-12. Cited in this article [1]

[48]	van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease[J]. N Engl J Med, 2023, 388(1): 9-21. Cited in this article [1]

[49]	Liu KY, Villain N, Ayton S, et al. Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s disease[J]. Brain Commun, 2023, 5(3):fcad175. Cited in this article [1]

[50]	Thambisetty M, Howard R. Lecanemab trial in AD brings hope but requires greater clarity[J]. Nat Rev Neurol, 2023, 19(3): 132-133. Cited in this article [1]

[51]	Demattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice[J]. Neuron, 2012, 76(5): 908-920. Cited in this article [1]

[52]	Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease[J]. N Engl J Med, 2021, 384(18): 1691-1704. Cited in this article [1]

[53]	Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial[J]. JAMA, 2023, 330(6): 512. Cited in this article [2]

[54]	Aisen PS, Jimenez-Maggiora GA, Rafii MS, et al. Early-stage Alzheimer disease: getting trial-ready[J]. Nat Rev Neurol, 2022, 18(7): 389-399. Cited in this article [1]

[55]	Unanimous: FDA Advisory Committee Backs Donanemab[EB/OL]. ( 2024-06-10)[2024-08-09]. https://www.alzforum.org/news/community-news/unanimous-fda-advisory-committee-backs-donanemab Cited in this article [1]

[56]	Syed YY. Sodium oligomannate: first approval[J]. Drugs, 2020, 80(4): 441-444. Cited in this article [1]

[57]	Wang X, Xie Z, Yuan J, et al. Sodium oligomannate disrupts the adherence of Ribhigh bacteria to gut epithelia to block SAA-triggered Th1 inflammation in 5XFAD transgenic mice[J]. Cell Discov, 2024, 10(1):115. Cited in this article [1]

[58]	Lu J, Pan Q, Zhou J, et al. Pharmacokinetics, distribution, and excretion of sodium oligomannate, a recently approved anti-Alzheimer's disease drug in china[J]. J Pharm Anal, 2022, 12(1):145-155. Cited in this article [1]

[59]	Chen X, Chen X, Yan D, et al. GV-971 prevents severe acute pancreatitis by remodeling the microbiota-metabolic-immune axis[J]. Nat Commun, 2024, 15(1): 8278. Cited in this article [1]

[60]	Xiao S, Chan P, Wang T, et al. A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia[J]. Alzheimers Res Ther, 2021, 13(1):62. Cited in this article [1]

[61]	Zhang LF, Zhang YP, Lin PX, et al. Efficacy and safety of sodium oligomannate in the treatment of Alzheimer's disease[J]. Pak J Pharm Sci, 2022, 35(3):741-745. Cited in this article [1]

[62]	Chen Y, Lai M, Tao M, et al. Evaluating the efficacy and safety of Alzheimer's disease drugs: a meta-analysis and systematic review[J]. Medicine (Baltimore), 2024, 103(16): e37799. Cited in this article [1]

[63]	Chen Z, Wang X, Du S, et al. A review on traditional chinese medicine natural products and acupuncture intervention for Alzheimer's disease based on the neuroinflammatory[J]. Chin Med, 2024, 19(1): 35. Cited in this article [1]

[64]	Zhao J, Yang J, Ding L, et al. A review of the pathogenesis and chinese medicine intervention of Alzheimer's disease[J]. J Integr Neurosci, 2022, 22(1): 2. Cited in this article [1]